Trends in Drug Duplications in Swedish Older Adults: A Nationwide Register Study from 2006 to 2021
Drugs & Aging · 2024-09 · 41 (9) · 775-781
DOI: 10.1007/s40266-024-01145-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs & Aging, online erschienen am 13.09.2024. Verfasst von Tatiana Erhan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. Hauptthemen laut MEDLINE: Registries, Medication Errors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Forskningsrådet om Hälsa, Arbetsliv och Välfärd, Riksbankens Jubileumsfond, Karolinska Institute.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
BACKGROUND: Drug duplication (DD), the use of two identical drugs simultaneously, is a medication error increasing the risk of adverse drug events. We describe the trends and implicated drugs in potential DD in older adults in Sweden from 2006 to 2021. METHODS: We conducted a register-based, repeated cross-sectional study of all older adults (aged ≥65 years) dispensed drugs at a community pharmacy in 2006-2021. DD was defined as a ≥30-day overlap of two dispensations of drugs with the same 5th level (chemical substance) Anatomical Therapeutic Chemical (ATC) classification, but with different brand names, within a 3-month period each year. RESULTS: Among Swedish older adults with ordinary prescriptions (i.e. multidose excluded; n ≈ 1,200,000-1,600,000 per year), the prevalence of potential DD increased from 5.2% to 10.6% in 65- to 79-year-olds and from 7.0% to 11.7% in those aged ≥80 years. The drug groups (ATC level 3; pharmacological subgroup) most frequently implicated in DD in 2006 were β-blocking agents, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers, and in 2021 Vitamin B12 and folic acid, β-blocking agents and angiotensin II receptor blockers. CONCLUSIONS: DD represents a common but unnecessary and potentially hazardous medication error. Our results indicate that during the last two decades, the prevalence has almost doubled in older adults with ordinary prescriptions, reaching 11% in 2021. More national efforts are needed to revert this trend, including a nationally available complete drug list for all patients, and prescriber support to detect DD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. johan.fastbom@ki.se.
ORCID-Profile: Johan Fastbom
Förderung
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Riksbankens Jubileumsfond
- Karolinska Institute
Zitieren
APA
Erhan, T., Wastesson, J. W., & Fastbom, J. (2024). Trends in Drug Duplications in Swedish Older Adults: A Nationwide Register Study from 2006 to 2021. Drugs & Aging, 41(9), 775-781. https://doi.org/10.1007/s40266-024-01145-6
Vancouver
Erhan T, Wastesson JW, Fastbom J. Trends in Drug Duplications in Swedish Older Adults: A Nationwide Register Study from 2006 to 2021. Drugs & Aging. 2024;41(9):775-781. doi:10.1007/s40266-024-01145-6
BibTeX
@article{Erhan2024,
author = {Erhan, Tatiana and Wastesson, Jonas W and Fastbom, Johan},
title = {Trends in Drug Duplications in Swedish Older Adults: A Nationwide Register Study from 2006 to 2021},
journal = {Drugs & Aging},
year = {2024},
volume = {41},
number = {9},
pages = {775--781},
doi = {10.1007/s40266-024-01145-6}
}
EUVIMED